These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 7936252)

  • 1. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs.
    Weiss KL; Schroeder CE; Kastin SJ; Gibson JP; Yarrington JT; Heydorn WE; McBride RG; Sussman NM; Arezzo JC
    Neurology; 1994 Oct; 44(10):1944-9. PubMed ID: 7936252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain.
    Peyster RG; Sussman NM; Hershey BL; Heydorn WE; Meyerson LR; Yarrington JT; Gibson JP
    Epilepsia; 1995 Jan; 36(1):93-100. PubMed ID: 8001516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor.
    Yarrington JT; Gibson JP; Dillberger JE; Hurst G; Lippert B; Sussman NM; Heydorn WE; Marler RJ
    Toxicol Pathol; 1993; 21(5):480-9. PubMed ID: 8115824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of high-dose gamma-vinyl GABA (vigabatrin) administration on visual and somatosensory evoked potentials in dogs.
    Schroeder CE; Gibson JP; Yarrington J; Heydorn WE; Sussman NM; Arezzo JC
    Epilepsia; 1992; 33 Suppl 5():S13-25. PubMed ID: 1425496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor.
    Gibson JP; Yarrington JT; Loudy DE; Gerbig CG; Hurst GH; Newberne JW
    Toxicol Pathol; 1990; 18(2):225-38. PubMed ID: 2399411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles.
    Agosti R; Yasargil G; Egli M; Wieser HG; Wiestler OD
    Epilepsy Res; 1990 Jul; 6(2):166-70. PubMed ID: 2387287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-vision adverse events with vigabatrin therapy.
    Walker SD; Kälviäinen R
    Acta Neurol Scand Suppl; 2011; (192):72-82. PubMed ID: 22061182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors. Comparison of effects of ethanolamine-O-sulphate and vigabatrin.
    John RA; Rimmer EM; Williams J; Cole G; Fowler LJ; Richens A
    Biochem Pharmacol; 1987 May; 36(9):1467-73. PubMed ID: 3579985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of vigabatrin on evoked potentials in dogs.
    Arezzo JC; Schroeder CE; Litwak MS; Steward DL
    Br J Clin Pharmacol; 1989; 27 Suppl 1(Suppl 1):53S-60S. PubMed ID: 2757910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose vigabatrin (gamma-vinyl GABA)-induced damage in the immature rat brain.
    Sidhu RS; Del Bigio MR; Tuor UI; Seshia SS
    Exp Neurol; 1997 Apr; 144(2):400-5. PubMed ID: 9168839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vigabatrin edema.
    Cocito L; Maffini M
    Neurology; 1995 Nov; 45(11):2115-6. PubMed ID: 7501178
    [No Abstract]   [Full Text] [Related]  

  • 12. Gabapentin potentiation of the antiepileptic efficacy of vigabatrin in an in vitro model of epilepsy.
    Lücke A; Musshoff U; Köhling R; Osterfeld M; Mayer T; Wolf P; Schütte W; Speckmann EJ
    Br J Pharmacol; 1998 May; 124(2):370-6. PubMed ID: 9641555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration.
    Horton M; Rafay M; Del Bigio MR
    J Child Neurol; 2009 Dec; 24(12):1543-6. PubMed ID: 19773459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acute psychosis and vigabatrin in childhood].
    Chiaretti A; Castorina M; Tortorolo L; Piastra M; Polidori G
    Pediatr Med Chir; 1994; 16(5):489-90. PubMed ID: 7885961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
    Grant SM; Heel RC
    Drugs; 1991 Jun; 41(6):889-926. PubMed ID: 1715266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging.
    Jackson GD; Williams SR; Weller RO; van Bruggen N; Preece NE; Williams SC; Butler WH; Duncan JS
    Epilepsy Res; 1994 May; 18(1):57-66. PubMed ID: 8088257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.
    Petroff OA; Rothman DL
    Mol Neurobiol; 1998 Feb; 16(1):97-121. PubMed ID: 9554704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of chronic treatment with the GABA transaminase inhibitors gamma-vinyl GABA and ethanolamine O-sulphate on the in vitro GABA release from rat hippocampus.
    Qume M; Fowler LJ
    Br J Pharmacol; 1997 Oct; 122(3):539-45. PubMed ID: 9351512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral toxicity of vigabatrin in immature rats: characterization of intramyelinic edema.
    Walzer M; Bekersky I; Wanaski S; Collins S; Jortner B; Patterson R; Garman R; Sagar S; Tolbert D
    Neurotoxicology; 2011 Dec; 32(6):963-74. PubMed ID: 21473881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats.
    Engelborghs S; Pickut BA; D'Hooge R; Wiechert P; Haegele K; De Deyn PP
    Arzneimittelforschung; 1998 Jul; 48(7):713-6. PubMed ID: 9706369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.